Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

Now Viewing

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.

Pipe introduces the latest hemophilia A therapies, Altuviiio and Roctavian, shedding light on their eligibility criteria and potential benefits for specific patient populations. Altuviiio, a high-sustained factor-VIII prophylaxis, offers a once-weekly dosing strategy with remarkable pharmacokinetic characteristics. This not only aids in managing bleeding events but also transforms surgical approaches, potentially eliminating the need for factor VIII replacement during recovery. Roctavian, a gene therapy, utilizes an adeno-associated viral vector for one-time treatment, resulting in sustained factor VIII expression. The majority of patients may cease prophylaxis post treatment. While the long-term data is evolving, Roctavian shows promise in improving joint outcomes, bleed rates, and quality of life. However, it comes with limitations, including eligibility restrictions for adults with liver health considerations and those with neutralizing antibodies against the AAV vector. Pipe emphasizes the potential impact on factor consumption reduction with Altuviiio and the transformative nature of Roctavian in minimizing the need for ongoing prophylaxis. As these therapies revolutionize hemophilia A treatment, the discussion explores their clinical utility, eligibility challenges, and implications for patient care.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.